| HOME >> BIOLOGY >> TECHNOLOGY |
"From both breadth of information and research utility perspectives, NGS is most valuable when combined with other technologies like IHC and FISH to more comprehensively assess a patient's tumor,"said Sandeep Reddy , M.D., Clinical Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA) and Senior Medical Director at Caris Life Sciences. "Sequencing alone may provide relevant results in smaller percentages of cancer patients, giving the treating physician only part of the full molecular picture. In contrast, Caris provides more meaningful biomarker analysis and delivershighly thorough interrogation of important biomarkers in the cancer pathway. Additionally, Caris' approach also allows for compliance with FDA labeling on approved companion diagnostics."
With more than 45,000 patients profiled to date, Caris Life Sciences houses the most comprehensive collection of biomarker profiles in the industry today. Beyond obvious research implications, this extensive database provides clinicians with critical information about the prevalence of biomarkers in unexpected disease states, allowing them to select personalized, tailored therapy regimens for their patients.
About Caris Life Sciences
Caris Life Sciences is a leading biosciences company focused on fulfilling the promise of personalized medicine. Caris' Molecular Intelligence™ Service (MI Profile™) correlates molecular data generated from a patient's tumor with biomarker/drug associations derived from the world's leading clinical cancer literature. This service uses the most advanced and clinically-relevant technologies to provide physicians with information to aid in the selection of personalized cancer treatments more likely to work for each patient. Caris is also developing a series of
'/>"/>
| SOURCE Caris Life Sciences Copyright©2012 PR Newswire. All rights reserved |